Guardino, Ellie
Genentech
3 papers on CoChatORCID 0000-0003-3617-5788
Most cited papers
- Verified
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 3,834
- Verified
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., & Miles, D. (2014) · Cancer
HER2/EGFR in Cancer ResearchCancer survivorship and care
Cited by 126
- Verified
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., et al. (2020) · Proceedings of the National Academy of Sciences
Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments
Cited by 91
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free